Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial (Q43712233)

26 November 2017

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial (English)

1 reference

26 November 2017

1 reference

1 reference

3

1 reference

26 November 2017

1

A F C Okines

1 reference

26 November 2017

L C Thompson

2

1 reference

26 November 2017

A Wotherspoon

4

1 reference

26 November 2017

J S Reis-Filho

5

1 reference

26 November 2017

R E Langley

6

1 reference

26 November 2017

T S Waddell

7

1 reference

26 November 2017

D Noor

8

1 reference

26 November 2017

Z Eltahir

9

1 reference

26 November 2017

R Wong

10

1 reference

26 November 2017

S Stenning

11

1 reference

26 November 2017

11 December 2012

1 reference

26 November 2017

1 reference

26 November 2017

24

1 reference

26 November 2017

5

1 reference

26 November 2017

1253-1261

1 reference

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

26 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

HER2/neu in systemic therapy for women with breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Culprit and victim -- DNA topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS622

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS622

1 reference

26 November 2017

1 reference